An active trend of immunotherapy combination regimen as second-line therapy for advanced biliary tract cancer: A multicenter retrospective study.
Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuemiao Chen(Wenzhou Central Hospital), Pengfei Zeng(Zhejiang Medical and Health Group Hangzhou Hospital), Qi Xu(Zhejiang Cancer Hospital), Qing Wei(Chinese Academy of Sciences), Jing‐Jing Li(Shanghai Institute of Nutrition and Health), Haimin Weng(Zhejiang Chinese Medical University)
Cited by 0
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412